{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:50:59Z","timestamp":1781819459911,"version":"3.54.5"},"reference-count":159,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":1095,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jpainsymman.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T19:49:30Z","timestamp":1580240970000},"page":"135-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Chronic Obstructive Pulmonary Disease: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions"],"prefix":"10.1016","volume":"60","author":[{"given":"Andrea","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyer","family":"Balter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1873-7794","authenticated-orcid":false,"given":"Kirsten","family":"Wentlandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2020.01.009_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib2","first-page":"3","article-title":"Palliative care: a review of past changes and future trends","volume":"15","author":"Higginson","year":"1993","journal-title":"J\u00a0Public Health Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamainternmed.2016.1200","article-title":"Quality of end-of-life care provided to patients with different serious illnesses","volume":"176","author":"Wachterman","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib4","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/thorax.55.12.1000","article-title":"How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer","volume":"55","author":"Gore","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archinte.166.3.326","article-title":"Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer","volume":"166","author":"Au","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1513\/AnnalsATS.201510-666PS","article-title":"Inadequate palliative care in chronic lung disease. An issue of health care inequality","volume":"13","author":"Brown","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib7","first-page":"257","article-title":"A\u00a0comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness","volume":"5","author":"Kheshti","year":"2016","journal-title":"J\u00a0Res Pharm Pract"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(11)60990-2","article-title":"Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study","volume":"378","author":"Gershon","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"issue":"4 Suppl","key":"10.1016\/j.jpainsymman.2020.01.009_bib11","doi-asserted-by":"crossref","first-page":"235S","DOI":"10.1378\/chest.113.4_Supplement.235S","article-title":"COPD: overview of definitions, epidemiology, and factors influencing its development","volume":"113","author":"Rennard","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib12","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Standardisation of lung function testing","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib13","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1001\/archinte.164.21.2321","article-title":"The burden of symptoms among community-dwelling older persons with advanced chronic disease","volume":"164","author":"Walke","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/014107680710000512","article-title":"Palliative care in chronic obstructive pulmonary disease: a review for clinicians","volume":"100","author":"Seamark","year":"2007","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.hrtlng.2014.04.004","article-title":"Symptom burden in stable COPD patients with moderate or severe airflow limitation","volume":"43","author":"Eckerblad","year":"2014","journal-title":"Heart Lung"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(17)32127-X","article-title":"Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease","volume":"390","author":"Maddocks","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10354-009-0727-z","article-title":"Management of dyspnea in patients with chronic obstructive pulmonary disease","volume":"159","author":"Abernethy","year":"2009","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/SPC.0b013e328338f921","article-title":"Common approaches to dyspnoea management in advanced life-limiting illness","volume":"4","author":"Abernethy","year":"2010","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/jpm.2012.0505","article-title":"The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam","volume":"16","author":"Allcroft","year":"2013","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib20","first-page":"12","article-title":"Breathlessness in advanced disease. 2: Patient assessment and management","volume":"106","author":"Barnes","year":"2010","journal-title":"Nurs Times"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jpm.2011.0110","article-title":"Dyspnea review for the palliative care professional: treatment goals and therapeutic options","volume":"15","author":"Kamal","year":"2012","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib22","series-title":"Oxford textbook of palliative medicine","first-page":"1254","author":"Cherny","year":"2015"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(09)61301-5","article-title":"Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index","volume":"374","author":"Puhan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002152","article-title":"Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts","volume":"2","author":"Puhan","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib26","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1378\/chest.13-1328","article-title":"Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index","volume":"145","author":"Almagro","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib27","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2147\/COPD.S137868","article-title":"Prognostic variables and scores identifying the end of life in COPD: a systematic review","volume":"12","author":"Smith","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1183\/09031936.00126107","article-title":"Palliative and end-of-life care for patients with severe COPD","volume":"32","author":"Curtis","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib29","first-page":"CD010744","article-title":"Smoking cessation for people with chronic obstructive pulmonary disease","volume":"8","author":"van Eerd","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib30","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.2147\/COPD.S145253","article-title":"Acute exacerbations of COPD: risk factors for failure and relapse","volume":"12","author":"Mantero","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1513\/AnnalsATS.201708-626OC","article-title":"Beta-blocker therapy and clinical outcomes in patients with moderate COPD and heightened cardiovascular risk: an observational sub-study of SUMMIT","volume":"15","author":"Dransfield","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.chest.2018.01.008","article-title":"Beta-blockers in COPD: a cohort study from the TONADO Research Program","volume":"153","author":"Maltais","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/thoraxjnl-2012-201945","article-title":"Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension","volume":"67","author":"Stefan","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib34","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2147\/COPD.S144333","article-title":"Beta-blocker under-use in COPD patients","volume":"12","author":"Lim","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib35","series-title":"Global strategy for the Diagnosis, Management, and Prevention of COPD","year":"2017"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib36","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/COPD.S148601","article-title":"Letter to the editor regarding: \u201cDevelopment of the ProPal-COPD tool to identify patients with COPD for proactive palliative care\u201d","volume":"12","author":"Almagro","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib37","first-page":"486","article-title":"Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers","volume":"14","author":"Yu","year":"2011","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib38","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.rmed.2011.07.001","article-title":"Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD","volume":"105","author":"Yu","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1378\/chest.15-0084","article-title":"A\u00a0systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD","volume":"148","author":"Rodrigo","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib40","first-page":"CD008989","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","volume":"10","author":"Farne","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/thorax.58.7.580","article-title":"Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: cochrane systematic review and meta-analysis","volume":"58","author":"Ram","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib42","first-page":"CD010177","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease","volume":"10","author":"Kew","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/thx.2004.033266","article-title":"Addition of salmeterol to existing treatment in patients with COPD: a 12 month study","volume":"61","author":"Stockley","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib45","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1164\/ajrccm.163.5.9903053","article-title":"Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease","volume":"163","author":"Rennard","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.129.3.509","article-title":"Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD","volume":"129","author":"van Noord","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00003495-200060020-00005","article-title":"Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease","volume":"60","author":"Cazzola","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1378\/chest.112.2.336","article-title":"Salmeterol reduces dyspnea and improves lung function in patients with COPD","volume":"112","author":"Ramirez-Venegas","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib50","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.290.17.2301","article-title":"Contemporary management of chronic obstructive pulmonary disease: scientific review","volume":"290","author":"Sin","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib51","series-title":"Lexicomp Online","year":"2018"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib53","year":"2019"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib54","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1183\/09031936.02.00301702","article-title":"Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study","volume":"20","author":"Wadbo","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib55","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S0002-9343(96)80037-4","article-title":"Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease","volume":"100","author":"Colice","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-143-5-200509060-00007","article-title":"Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial","volume":"143","author":"Niewoehner","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A\u00a06-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.118.5.1294","article-title":"The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group","volume":"118","author":"Casaburi","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1183\/09031936.06.00062705","article-title":"The effect of tiotropium on exacerbations and airflow in patients with COPD","volume":"27","author":"Dusser","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A\u00a0long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib62","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib63","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0873-2159(15)30121-5","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial)","volume":"15","author":"Tashkin","year":"2009","journal-title":"Rev Port Pneumol"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib64","series-title":"Theophyllines (CPhA monograph)","year":"2017"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib65","first-page":"CD003902","article-title":"Oral theophylline for chronic obstructive pulmonary disease","volume":"4","author":"Ram","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/thx.53.4.269","article-title":"Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease","volume":"53","author":"Tsukino","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1378\/chest.115.1.38","article-title":"Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice","volume":"115","author":"Mahon","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib68","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/thx.49.4.332","article-title":"Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease","volume":"49","author":"Fink","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib69","first-page":"811","article-title":"Physiological and neuropsychological effects of theophylline in chronic obstructive pulmonary disease","volume":"30","author":"Newman","year":"1994","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/thx.48.3.227","article-title":"Value of theophylline treatment in patients handicapped by chronic obstructive lung disease","volume":"48","author":"McKay","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib71","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1378\/chest.104.4.1101","article-title":"Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease","volume":"104","author":"Kirsten","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib72","first-page":"126","article-title":"Hyperinflation, trapped gas and theophylline in chronic obstructive pulmonary disease","volume":"48","author":"Waterhouse","year":"1993","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1164\/ajrccm\/143.2.245","article-title":"Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease","volume":"143","author":"Berry","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib74","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/ajrccm\/145.3.540","article-title":"Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease","volume":"145","author":"Martin","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF01740657","article-title":"Nocturnal oxygen saturation and sleep quality in patients with advanced chronic obstructive pulmonary disease during treatment with moderate dose CR-theophylline","volume":"43","author":"Brander","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"issue":"4 Pt 1","key":"10.1016\/j.jpainsymman.2020.01.009_bib76","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1164\/ajrccm\/148.4_Pt_1.1030","article-title":"Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease","volume":"148","author":"Mulloy","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib77","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib78","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1164\/rccm.200404-543OC","article-title":"Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease","volume":"170","author":"Sin","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib79","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2005.04.025","article-title":"The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients","volume":"99","author":"Ozol","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2466-5-3","article-title":"Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis","volume":"5","author":"Gan","year":"2005","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib81","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/thx.2005.042200","article-title":"C-reactive protein in patients with COPD, control smokers and non-smokers","volume":"61","author":"Pinto-Plata","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib83","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease","volume":"9","author":"Nannini","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00408-017-9990-8","article-title":"Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT study","volume":"195","author":"Morjaria","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib86","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.2147\/COPD.S172240","article-title":"Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?","volume":"13","author":"Tashkin","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib87","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results","volume":"34","author":"Crim","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib88","first-page":"e81","article-title":"Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults: executive summary","volume":"19","author":"Lougheed","year":"2012","journal-title":"Can Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib89","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib90","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib91","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib92","first-page":"222","article-title":"CTS position statement: pharmacotherapy in patients with COPD\u2014an update","volume":"1","author":"Bourbeau","year":"2017","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib93","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa023161","article-title":"Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease","volume":"348","author":"Aaron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1465-9921-15-37","article-title":"Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease","volume":"15","author":"Horita","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib95","first-page":"CD005374","article-title":"Oral corticosteroids for stable chronic obstructive pulmonary disease","volume":"3","author":"Walters","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib96","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1183\/09031936.01.17303800","article-title":"Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics","volume":"17","author":"Sin","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib97","first-page":"129","article-title":"Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease","volume":"11","author":"Soto","year":"2005","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.11.1.1","article-title":"Update on the therapeutic potential of PDE4 inhibitors","volume":"11","author":"Dyke","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"Pt 1","key":"10.1016\/j.jpainsymman.2020.01.009_bib99","first-page":"1","article-title":"PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization","volume":"370","author":"Houslay","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib101","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2165\/00003495-200363190-00002","article-title":"Therapy for chronic obstructive pulmonary disease in the 21st century","volume":"63","author":"Donnelly","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib102","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(05)17708-3","article-title":"Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease","volume":"365","author":"Lipworth","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib103","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200212-1490OC","article-title":"Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease","volume":"168","author":"Gamble","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib104","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/thorax.58.7.573","article-title":"Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD","volume":"58","author":"Profita","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib105","first-page":"1165","article-title":"Roflumilast Altana Pharma","volume":"3","author":"Reid","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib106","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543784.10.7.1361","article-title":"Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease","volume":"10","author":"Giembycz","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib107","first-page":"CD002309","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","volume":"5","author":"Chong","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib108","series-title":"Product monograph: Daxas","year":"2017"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib109","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1378\/chest.106.5.1532","article-title":"Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Task Group on Mucoactive Drugs","volume":"106","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib110","first-page":"1176","article-title":"Mucoactive agents for airway mucus hypersecretory diseases","volume":"52","author":"Rogers","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib111","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-4-13","article-title":"Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]","volume":"4","author":"Black","year":"2004","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib112","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-134-7-200104030-00016","article-title":"Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence","volume":"134","author":"Bach","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib113","doi-asserted-by":"crossref","first-page":"595","DOI":"10.7326\/0003-4819-134-7-200104030-00015","article-title":"Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease","volume":"134","author":"Snow","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib114","first-page":"179","article-title":"Effect of mucolytic and expectorant drugs on tracheobronchial clearance in chronic bronchitis","volume":"110","author":"Clarke","year":"1980","journal-title":"Eur J Respir Dis Suppl"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib115","first-page":"441","article-title":"The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease","volume":"3","author":"Richardson","year":"1978","journal-title":"Pharmacol Ther B"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib116","first-page":"CD001287","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease","volume":"7","author":"Poole","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib117","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib118","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1378\/chest.12-2357","article-title":"High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study","volume":"144","author":"Tse","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib119","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5414\/CPP49041","article-title":"Erdosteine affects eicosanoid production in COPD","volume":"49","author":"Dal Negro","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib120","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib121","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00791-2016","article-title":"Management of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"49","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib122","first-page":"CD010257","article-title":"Antibiotics for exacerbations of chronic obstructive pulmonary disease","volume":"12","author":"Vollenweider","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib123","first-page":"CD009764","article-title":"Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)","volume":"11","author":"Herath","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib124","doi-asserted-by":"crossref","first-page":"e0121257","DOI":"10.1371\/journal.pone.0121257","article-title":"Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis","volume":"10","author":"Ni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib125","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1164\/ajrccm.156.1.9512074","article-title":"Rheology of cystic fibrosis sputum after in\u00a0vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I","volume":"156","author":"King","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib127","first-page":"199","article-title":"Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol","volume":"117","author":"Pavia","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A\u00a0controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10 Pt 1","key":"10.1016\/j.jpainsymman.2020.01.009_bib130","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1164\/ajrccm.164.10.2104024","article-title":"Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease","volume":"164","author":"Taube","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib131","first-page":"327","article-title":"Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: a randomized trial","volume":"54","author":"Valderramas","year":"2009","journal-title":"Respir Care"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib132","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMra030415","article-title":"Management of chronic obstructive pulmonary disease","volume":"350","author":"Sutherland","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib133","first-page":"681","article-title":"Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib134","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-93-3-391","article-title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group","volume":"93","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib135","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM199509143331107","article-title":"Long-term oxygen therapy","volume":"333","author":"Tarpy","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib136","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1001\/jama.290.17.2313","article-title":"Contemporary management of chronic obstructive pulmonary disease: clinical applications","volume":"290","author":"Man","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib137","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","article-title":"Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society","volume":"155","author":"Qaseem","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib138","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1465-9921-6-54","article-title":"Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality\u2014a systematic review","volume":"6","author":"Puhan","year":"2005","journal-title":"Respir Res"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib139","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1378\/chest.117.4.976","article-title":"Long-term effects of outpatient rehabilitation of COPD: a randomized trial","volume":"117","author":"Guell","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib140","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1378\/chest.128.6.3799","article-title":"The effects of pulmonary rehabilitation in the national emphysema treatment trial","volume":"128","author":"Ries","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib141","doi-asserted-by":"crossref","first-page":"823","DOI":"10.7326\/0003-4819-122-11-199506010-00003","article-title":"Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease","volume":"122","author":"Ries","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib142","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1378\/chest.07-0180","article-title":"Risks in using nonrigorous Spanish translations of asthma questionnaires","volume":"131","author":"Narvaez","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib143","first-page":"CD005305","article-title":"Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease","volume":"10","author":"Puhan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib144","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bmj.38258.662720.3A","article-title":"Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study","volume":"329","author":"Man","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/thx.2009.124164","article-title":"Outpatient pulmonary rehabilitation following acute exacerbations of COPD","volume":"65","author":"Seymour","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib146","first-page":"CD001001","article-title":"Lung volume reduction surgery for diffuse emphysema","volume":"10","author":"van Agteren","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib147","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.athoracsur.2013.03.088","article-title":"Heterogeneity of lung volume reduction surgery outcomes in patients selected by use of evidence-based criteria","volume":"95","author":"Lammi","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib148","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa030287","article-title":"A\u00a0randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema","volume":"348","author":"Fishman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib149","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.athoracsur.2005.07.055","article-title":"A\u00a0randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: a two-year study from Canada","volume":"81","author":"Miller","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib150","first-page":"1166","article-title":"Lung volume reduction surgery vs medical treatment: for patients with advanced emphysema","volume":"127","author":"Miller","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib151","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1378\/chest.128.5.3489","article-title":"Comparison of lung volume reduction surgery and physical training on health status and physiologic outcomes: a randomized controlled clinical trial","volume":"128","author":"Hillerdal","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib152","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJM200007273430402","article-title":"Effect of lung-volume-reduction surgery in patients with severe emphysema","volume":"343","author":"Geddes","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib153","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.athoracsur.2007.07.007","article-title":"Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients","volume":"84","author":"Pompeo","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib154","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtcvs.2006.12.062","article-title":"Lung-volume reduction surgery for pulmonary emphysema: improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year","volume":"133","author":"Lederer","year":"2007","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib155","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1378\/chest.123.4.1026","article-title":"A\u00a0prospective evaluation of lung volume reduction surgery in 200 consecutive patients","volume":"123","author":"Yusen","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib156","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201501-0126OC","article-title":"Effects of recipient age and diagnosis on health-related quality-of-life benefit of lung transplantation","volume":"192","author":"Singer","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib157","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.healun.2009.12.008","article-title":"Exercise training after lung transplantation: a systematic review","volume":"29","author":"Wickerson","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib158","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200605-587ST","article-title":"An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses","volume":"177","author":"Lanken","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib159","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cardfail.2003.09.006","article-title":"Consensus statement: palliative and supportive care in advanced heart failure","volume":"10","author":"Goodlin","year":"2004","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib160","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1089\/jpm.2013.0167","article-title":"Integration of palliative care in end-stage liver disease and liver transplantation","volume":"17","author":"Potosek","year":"2014","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.jpainsymman.2020.01.009_bib161","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10620-016-4339-3","article-title":"Palliative care quality indicators for patients with end-stage liver disease due to cirrhosis","volume":"62","author":"Walling","year":"2017","journal-title":"Dig Dis Sci"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392420300610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392420300610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:28:54Z","timestamp":1760131734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392420300610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0885392420300610"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.01.009","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Obstructive Pulmonary Disease: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}